Less contrast, same clarity? study aims to make heart surgery prep safer

NCT ID NCT05758701

Recruiting now Diagnosis Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study investigates whether using a lower dose of iodine contrast dye in CT scans can still produce high-quality images needed to plan a heart valve replacement procedure (TAVR). Normally, 100 ml of contrast is used, but reducing the dose may help avoid kidney injury and save resources. Participants scheduled for TAVR will receive a reduced contrast dose, and the images will be evaluated for diagnostic quality.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iodinated contrast agent (Omnipaque)
What this could lead to: If successful, this approach could reduce the amount of contrast dye needed for pre-surgery scans, lowering the risk of kidney injury and saving costs.
What could go wrong: The lower contrast dose might not produce images clear enough for safe surgical planning, and the study is limited to a specific patient group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSCATHETER AORTIC VALVE REPLACEMENT

Contacts and locations

Locations

University of Maryland Medical Center
RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.